跳至主要内容
临床试验/SLCTR/2024/011
SLCTR/2024/011尚未招募2 期

Anti-fibrotic effects of Silymarin among the patients of Nonalcoholic Fatty Liver Disease, a randomized control trial

Integrated Health Science Research and Development Fund0 个研究点开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Fatty liver on ultrasonography of the hepatobilliary system -
  • Hepatocellular steatosis is the hallmark of NAFLD, and steatosis in more than 5% of hepatocytes is required for the diagnosis of NAFLD. Fatty liver is diagnosed based on the following ultrasound parameters; parenchymal brightness, increased echogenicity of the liver parenchyma in comparison to the cortex of the right kidney, deep beam attenuation, bright vessel walls, and gallbladder wall definition.

排除标准

  • 1.Alcoholic Fatty Liver Disease
  • 2.Co-infection with HBV
  • 3.Co-infection with HCV
  • 4.Pregnancy

研究者

发起方
Integrated Health Science Research and Development Fund

相似试验